Kazia Therapeutics Limited (KZIA) Balance Sheet
KZIA balance sheet, FY2025
June 30, 2025 · Australian dollarsA$6.1M assets = A$14.4M liabilities + −A$8.3M equity
Liabilities exceed assets: shareholders’ equity is negative (−A$8.3M).
Both columns are drawn to the same scale: what KZIA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
KZIA financial health
Descriptive bands, not a rating. Fiscal FY2025.
KZIA balance sheet trends, FY2016–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | A$35.5MFY2016 | A$6.1MFY2025 | −17.8%/yr | |
| Total liabilities | A$1.6MFY2016 | A$14.4MFY2025 | +27.7%/yr | |
| Shareholders’ equity | A$33.9MFY2016 | −A$8.3MFY2025 | — | |
| Cash & short-term investments | A$33.5MFY2016 | A$4.3MFY2025 | −20.3%/yr | |
| Total debt | A$10,000FY2016 | A$396,000FY2025 | +50.5%/yr | |
| Net cash (debt) | A$33.4MFY2016 | A$3.9MFY2025 | −A$29.5M | |
| Working capital | A$32.7MFY2016 | −A$9.1MFY2025 | −A$41.8M | |
| Current ratio | 23.81FY2016 | 0.35FY2025 | −23.45 | |
| Debt / equity | 0.00FY2016 | 0.15FY2023 | +0.15 | |
| Shares outstanding | 89KFY2016 | 1.1MFY2025 | +32.1%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
KZIA assets
KZIA liabilities and equity
KZIA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
KZIA balance sheet in Australian dollars
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | A$4.3M | A$1.7M | A$5.2M | A$7.4M | A$27.6M | A$8.8M | A$5.5M | A$6.0M | A$14.5M | A$33.5M |
| Cash & equivalents | A$4.3M | A$1.7M | A$5.2M | A$7.4M | A$27.6M | A$8.8M | A$5.4M | A$6.0M | A$14.5M | A$33.5M |
| Short-term investments | — | — | — | — | — | — | A$0 | A$0 | A$0 | A$0 |
| Receivables | A$90,000 | A$133,000 | A$105,000 | A$51,000 | A$76,000 | A$439 | A$1.6M | A$1,130 | A$5,067 | A$91,000 |
| Inventory | A$0 | A$0 | −A$3.8M | A$0 | −A$83,999 | A$1 | −A$1.6M | A$0 | A$1 | A$434,000 |
| Other current assets | A$499,000 | A$4.4M | A$9.2M | A$2.0M | A$1.8M | A$1.9M | A$2.1M | A$3.3M | A$5.0M | A$112,000 |
| Total current assets | A$4.9M | A$6.1M | A$10.8M | A$9.4M | A$29.4M | A$10.7M | A$7.5M | A$9.3M | A$19.5M | A$34.1M |
| Property, plant & equipment (net) | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$1,000 | A$489,605 | A$592,000 |
| Goodwill & intangible assets | A$1.1M | A$15.4M | A$17.3M | A$19.1M | A$22.0M | A$12.4M | A$13.5M | A$14.6M | A$15.9M | A$822,000 |
| Long-term investments | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$168,000 | A$4.3M | A$22,000 | A$13,000 |
| Other non-current assets | A$40,000 | A$40,000 | A$43,000 | A$7.3M | A$6.7M | A$0 | A$0 | A$0 | A$0 | A$0 |
| Total assets | A$6.1M | A$21.6M | A$28.1M | A$35.9M | A$58.1M | A$23.1M | A$21.2M | A$28.2M | A$35.9M | A$35.5M |
| Liabilities | ||||||||||
| Accounts payable | A$5.6M | A$4.5M | A$857,000 | A$1.5M | A$1.9M | A$1.7M | A$1.1M | A$1.4M | A$1.2M | A$512,000 |
| Short-term debt | A$396,000 | A$634,000 | A$1.8M | A$1.8M | — | — | A$0 | A$84,000 | A$10,000 | A$10,000 |
| Deferred revenue | — | — | −A$1.8M | −A$1.8M | — | — | — | A$138,000 | A$41,000 | A$900,000 |
| Total current liabilities | A$14.1M | A$25.8M | A$7.6M | A$6.7M | A$8.3M | A$5.1M | A$2.2M | A$3.9M | A$5.4M | A$1.4M |
| Long-term debt | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 |
| Lease obligations | — | — | — | — | — | — | A$0 | A$84,000 | A$10,000 | A$10,000 |
| Other long-term liabilities | A$309,000 | A$5.8M | A$8.5M | A$10.9M | A$11.9M | A$3.9M | A$4.8M | A$5.0M | A$5.2M | A$154,000 |
| Total liabilities | A$14.4M | A$31.6M | A$16.0M | A$17.6M | A$20.2M | A$8.9M | A$7.0M | A$8.9M | A$10.6M | A$1.6M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | A$123.0M | A$101.6M | A$97.5M | A$84.5M | A$80.3M | A$48.8M | A$36.6M | A$31.6M | A$193.8M | A$191.3M |
| Retained earnings (deficit) | −A$134.8M | −A$115.1M | −A$89.1M | −A$68.6M | −A$44.2M | −A$36.2M | −A$24.9M | −A$14.6M | −A$171.0M | −A$160.5M |
| Treasury stock | — | — | — | — | — | — | A$0 | A$0 | A$0 | A$0 |
| Accumulated other comprehensive income | A$3.1M | A$3.5M | A$3.7M | A$2.4M | A$1.8M | A$1.1M | A$2.0M | A$1.8M | A$1.9M | A$1.4M |
| Minority interest | — | — | — | — | — | — | A$0 | A$0 | A$0 | A$0 |
| Total shareholders' equity | −A$8.3M | −A$10.0M | A$12.1M | A$18.3M | A$37.9M | A$14.1M | A$14.2M | A$19.2M | A$25.3M | A$33.9M |
| Key figures | ||||||||||
| Total debt | A$396,000 | A$634,000 | A$1.8M | A$1.8M | — | — | A$0 | A$84,000 | A$10,000 | A$10,000 |
| Net cash (debt) | A$3.9M | A$1.0M | A$3.4M | A$5.5M | — | — | A$5.5M | A$5.9M | A$14.4M | A$33.4M |
| Working capital | −A$9.1M | −A$19.7M | A$3.2M | A$2.7M | A$21.1M | A$5.6M | A$5.3M | A$5.4M | A$14.1M | A$32.7M |
| Tangible book value | −A$9.4M | −A$25.4M | −A$5.2M | −A$864,000 | A$15.8M | A$1.7M | A$701,000 | A$4.7M | A$9.4M | A$33.1M |
| Shares outstanding | 1.1M | 480K | 369K | 265K | 235K | 152K | 120K | 101K | 98K | 89K |
| Current ratio | 0.35 | 0.24 | 1.42 | 1.40 | 3.53 | 2.10 | 3.42 | 2.38 | 3.62 | 23.81 |
| Quick ratio | 0.32 | 0.07 | 0.71 | 1.10 | 3.32 | 1.73 | 3.18 | 1.53 | 2.69 | 23.42 |
| Debt / equity | — | — | 0.15 | 0.10 | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity / assets | −137.0% | −46.4% | 42.9% | 50.9% | 65.2% | 61.2% | 67.0% | 68.3% | 70.6% | 95.5% |
| Dec '25 | Sep '25 | Jun '25 | Dec '24 | Sep '24 | Jun '24 | Dec '23 | Sep '23 | Jun '23 | Dec '22 | Sep '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & short-term investments | A$69.4M | A$4.3M | A$4.3M | A$3.1M | A$1.7M | A$1.7M | A$3.6M | A$5.2M | A$5.2M | A$4.4M | A$7.4M |
| Cash & equivalents | A$69.4M | A$4.3M | A$4.3M | A$3.1M | A$1.7M | A$1.7M | A$3.6M | A$5.2M | A$5.2M | A$4.4M | A$7.4M |
| Receivables | A$315,225 | A$90,000 | A$0 | A$88,445 | A$133,000 | A$0 | A$65,393 | A$105,000 | A$105,644 | A$700,969 | A$700,969 |
| Inventory | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | −A$65,393 | −A$105,034 | A$0 | A$0 | A$0 |
| Other current assets | A$210,291 | A$499,000 | A$589,000 | A$253,935 | A$4.4M | A$4.5M | A$4.4M | A$5.5M | A$5.4M | A$824,716 | A$1.4M |
| Total current assets | A$69.9M | A$4.9M | A$4.9M | A$3.4M | A$6.1M | A$6.1M | A$8.0M | A$10.8M | A$10.8M | A$5.9M | A$9.4M |
| Property, plant & equipment (net) | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 |
| Goodwill & intangible assets | A$1.1M | A$1.1M | A$1.1M | A$14.5M | A$15.4M | A$15.4M | A$16.3M | A$17.3M | A$17.3M | A$18.2M | A$19.1M |
| Long-term investments | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 |
| Other non-current assets | A$39,961 | A$40,000 | A$40,000 | A$40,000 | A$40,000 | A$40,000 | A$40,000 | A$43,000 | A$42,922 | A$3.7M | A$7.3M |
| Total assets | A$71.0M | A$6.1M | A$6.1M | A$17.9M | A$21.6M | A$21.6M | A$24.4M | A$28.1M | A$28.1M | A$27.8M | A$35.9M |
| Liabilities | |||||||||||
| Accounts payable | A$6.1M | A$5.6M | A$5.6M | A$6.3M | A$4.5M | A$4.5M | A$1.0M | A$857,000 | A$857,312 | A$2.3M | A$1.5M |
| Short-term debt | A$98,708 | A$396,000 | — | A$140,737 | A$634,000 | — | A$359,300 | A$1.8M | A$1.8M | A$552,315 | A$1.8M |
| Deferred revenue | — | — | — | — | — | — | A$5.3M | A$4.2M | A$4.2M | — | — |
| Total current liabilities | A$24.3M | A$14.1M | A$14.1M | A$16.5M | A$25.8M | A$25.8M | A$11.3M | A$7.6M | A$7.6M | A$5.6M | A$6.7M |
| Long-term debt | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 |
| Other long-term liabilities | A$271,894 | A$309,000 | A$309,000 | A$5.2M | A$5.8M | A$5.8M | A$7.8M | A$8.5M | A$8.5M | A$10.7M | A$10.9M |
| Total liabilities | A$24.6M | A$14.4M | A$14.4M | A$21.7M | A$31.6M | A$31.6M | A$19.1M | A$16.0M | A$16.0M | A$16.3M | A$17.6M |
| Shareholders' equity | |||||||||||
| Common stock & paid-in capital | A$186.4M | A$123.0M | — | A$117.5M | A$101.6M | — | A$98.8M | A$97.5M | A$97.5M | A$90.3M | A$84.5M |
| Retained earnings (deficit) | −A$145.5M | −A$134.8M | −A$134.8M | −A$125.1M | −A$115.1M | −A$115.1M | −A$97.9M | −A$89.1M | −A$89.1M | −A$82.2M | −A$68.6M |
| Accumulated other comprehensive income | A$5.5M | A$3.1M | — | A$3.4M | A$3.5M | — | A$4.4M | A$3.7M | −A$741,790 | A$3.4M | A$2.4M |
| Total shareholders' equity | A$46.4M | −A$8.3M | −A$8.3M | −A$3.8M | −A$10.0M | −A$10.0M | A$5.3M | A$12.1M | A$12.1M | A$11.6M | A$18.3M |
| Key figures | |||||||||||
| Total debt | A$98,708 | A$396,000 | — | A$140,737 | A$634,000 | — | A$359,300 | A$1.8M | A$1.8M | A$552,315 | A$1.8M |
| Net cash (debt) | A$69.3M | A$3.9M | — | A$2.9M | A$1.0M | — | A$3.2M | A$3.4M | A$3.4M | A$3.8M | A$5.5M |
| Working capital | A$45.6M | −A$9.1M | −A$9.1M | −A$13.1M | −A$19.7M | −A$19.7M | −A$3.3M | A$3.2M | A$3.2M | A$333,829 | A$2.7M |
| Tangible book value | A$45.3M | −A$9.4M | −A$9.4M | −A$18.3M | −A$25.4M | −A$25.4M | −A$11.1M | −A$5.2M | −A$5.2M | −A$6.6M | −A$864,369 |
| Shares outstanding | 3.1M | 1.6M | 809.4M | 850K | 575K | 332.9M | 480K | 456K | 236.3M | 291K | 266K |
| Current ratio | 2.87 | 0.35 | 0.35 | 0.21 | 0.24 | 0.24 | 0.71 | 1.42 | 1.42 | 1.06 | 1.40 |
| Quick ratio | 2.86 | 0.32 | 0.31 | 0.19 | 0.07 | 0.06 | 0.32 | 0.71 | 0.71 | 0.91 | 1.20 |
| Debt / equity | 0.00 | — | — | — | — | — | 0.07 | 0.15 | 0.15 | 0.05 | 0.10 |
| Equity / assets | 65.3% | −137.0% | −137.0% | −21.3% | −46.4% | −46.4% | 21.6% | 42.9% | 42.9% | 41.6% | 50.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in Australian dollars as reported (latest annual report filed November 7, 2025); data from EODHD.
KZIA financial position
At the end of fiscal 2025 (June 30, 2025), Kazia Therapeutics had total assets of A$6.1 million (down 71.9% from a year earlier), total liabilities of A$14.4 million and shareholders' equity of -A$8.3 million. It held A$4.3 million in cash and short-term investments against A$0.4 million of debt, a net cash position of A$3.9 million. Its current ratio was 0.35. In the latest quarter (ended December 31, 2025) total assets were A$71.0 million and equity A$46.4 million.
Related: KZIA income statement, KZIA cash flow statement, KZIA key metrics. See the KZIA stock overview for the latest quote and news.
KZIA balance sheet FAQ
What are Kazia Therapeutics's total assets?
Kazia Therapeutics reported total assets of A$6.1 million at the end of fiscal 2025 (June 30, 2025), compared with A$21.6 million a year earlier.
How much debt does Kazia Therapeutics have?
Kazia Therapeutics had A$0.4 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was —.
How much cash does Kazia Therapeutics have?
Kazia Therapeutics held A$4.3 million in cash and short-term investments at the end of fiscal 2025; with A$0.4 million of debt that is net cash of A$3.9 million.
What is Kazia Therapeutics's book value?
Kazia Therapeutics's shareholders' equity (book value) was -A$8.3 million at the end of fiscal 2025.
What is Kazia Therapeutics's current ratio?
Kazia Therapeutics had current assets of A$4.9 million and current liabilities of A$14.1 million, a current ratio of 0.35 (current liabilities exceed current assets).
How much goodwill does Kazia Therapeutics have?
Kazia Therapeutics carried A$1.1 million of goodwill and intangible assets, 17.9% of total assets, at the end of fiscal 2025.